» Articles » PMID: 2892478

Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses

Overview
Specialty Psychiatry
Date 1988 Jan 1
PMID 2892478
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

The clinical use of antipsychotic agents may be enhanced by considering their dose-effect characteristics. In particular, assessment of immediate and later follow-up treatment of psychotic patients (1) indicates that moderate doses are adequate for most patients, (2) fails to support the utility of unusually high doses, and (3) even suggests the existence of a biphasic relationship of antipsychotic efficacy to dose of neuroleptics and possibly to plasma concentrations of the drugs as well. Trends toward lesser overall clinical benefits of high doses may reflect untoward extrapyramidal or other central nervous system effects leading to behavioral and cognitive symptoms. Thus, moderate doses of neuroleptics appear, on average, to be about as effective as, and probably safer than, the larger doses that have been popular in the United States in recent years.

Citing Articles

Randomized open-label study of second-generation antipsychotics for the treatment of schizophrenia: 104-week final results of the JUMPs study assessing treatment discontinuation, remission, and social functioning.

Ishigooka J, Nakagome K, Ohmori T, Iwata N, Inada K, Iga J BMC Psychiatry. 2024; 24(1):600.

PMID: 39237918 PMC: 11376064. DOI: 10.1186/s12888-024-06031-4.


Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study.

Ishigooka J, Nakagome K, Ohmori T, Iwata N, Inada K, Iga J Psychiatry Clin Neurosci. 2021; 76(1):22-31.

PMID: 34626144 PMC: 9299006. DOI: 10.1111/pcn.13304.


Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia: A Meta-analysis.

Leucht S, Bauer S, Siafis S, Hamza T, Wu H, Schneider-Thoma J JAMA Psychiatry. 2021; 78(11):1238-1248.

PMID: 34406325 PMC: 8374744. DOI: 10.1001/jamapsychiatry.2021.2130.


Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines.

Taylor R, Marwood L, Oprea E, DeAngel V, Mather S, Valentini B Int J Neuropsychopharmacol. 2020; 23(9):587-625.

PMID: 32402075 PMC: 7710919. DOI: 10.1093/ijnp/pyaa033.


Increasing antipsychotic dose for non response in schizophrenia.

Samara M, Klupp E, Helfer B, Rothe P, Schneider-Thoma J, Leucht S Cochrane Database Syst Rev. 2018; 5:CD011883.

PMID: 29750432 PMC: 6494602. DOI: 10.1002/14651858.CD011883.pub2.